Publications - Clive S . Zent, M.D.

Back to Research Profile

1. Van Dyke DL, Shanafelt TD, Call TG, Zent CS, Smoley SA, Rabe KG, Schwager SM, Sonbert JC, Slager SL, Kay NE. A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. Br J Haematol 2009 Nov 06. [Epub ahead of print]
   View PubMed
2. Ding W, Nowakowski GS, Knox TR, Boysen JC, Maas ML, Schwager SM, Wu W, Wellik LE, Dietz AB, Ghosh AK, Secreto CR, Medina KL, Shanafelt TD, Zent CS, Call TG, Kay NE. Bi-directional activation between mesenchymal stem cells and CLL B-cells: implication for CLL disease progression. Br J Haematol 2009 Nov; 147(4):471-83. Epub 2009 Sep 08.
   View PubMed
3. Shanafelt TD, Byrd JC, LaPLant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. Br J Haematol 2009 Sep; 146(6):660-4. Epub 2009 Jul 10.
   View PubMed
4. Shanafelt TD, Byrd JC, LaPlant B, Zent CS, Call T, Secreto C, Grever MR, Lin TS, Kay NE. Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. Br J Haematol 2009 Sep; 146(6):660-4.
   View PubMed
5. Shanafelt TD, Kay NE, Rabe KG, Call TG, Zent CS, Maddocks K, Jenkins G, Jelinek DF, Morice WG, Boysen J, Schwager S, Bowen D, Slager SL, Hanson CA. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol 2009 Aug 20; 27(24):3959-63. Epub 2009 Jul 20.
   View PubMed
6. Shanafelt TD, Call TG, Zent CS, LaPlant B, Bowen DA, Roos M, Secreto CR, Ghosh AK, Kabat BF, Lee MJ, Yang CS, Jelinek DF, Erlichman C, Kay NE. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009 Aug 10; 27(23):3808-14. Epub 2009 May 26.
   View PubMed
7. Zent CS, Shanafelt T. Management of autoimmune cytopenia complicating chronic lymphocytic leukemia. Leuk Lymphoma 2009 May 19; 1-2. [Epub ahead of print]
   View PubMed
8. Shanafelt TD, Kay NE, Jenkins G, Call TG, Zent CS, Jelinek DF, Morice WG, Boysen J, Zakko L, Schwager S, Slager SL, Hanson CA. B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood 2009 Apr 30; 113(18):4188-96. Epub 2008 Nov 17.
   View PubMed
9. Nowakowski GS, Hoyer JD, Shanafelt TD, Zent CS, Call TG, Bone ND, Laplant B, Dewald GW, Tschumper RC, Jelinek DF, Witzig TE, Kay NE. Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia. J Clin Oncol 2009 Apr 10; 27(11):1844-9. Epub 2009 Mar 02.
   View PubMed
10. Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Tun H, Sloan JA, Call TG. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res 2009 Feb; 33(2):263-70. Epub 2008 Jul 25.
    View PubMed
11. Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Tun H, Sloan JA, Call TG. The physician-patient relationship and quality of life: Lessons from chronic lymphocytic leukemia. Leuk Res 2009 Feb; 33(2):263-70.
    View PubMed
12. Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Tun H, Sloan JA, Call TG. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res 2009 Feb; 33(2):263-70. Epub 2008 Jul 25.
    View PubMed
13. Awan, FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung, N, Jelinek DF, Tschumper RC, Secreto CR, Lin TS, Grever MR, Shanafelt TD, Zent CS, Call TG, Heerema NA, Lozanski G, Byrd JC, Lucas DM. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 2009 Jan 15; 113(3):535-7.
    View PubMed
14. Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009 Jan 15; 115(2):363-72.
    View PubMed
15. Shanafelt TD, Jenkins G, Call TG, Zent CS, Slager S, Bowen DA, Schwager S, Hanson CA, Jelinek DF, Kay NE. Validation of a new prognostic index for patients with chronic lymphocytic leukemia. Cancer 2009 Jan 15; 115(2):363-72.
    View PubMed
16. Zent CS, Ding W, Reinalda MS, Schwager SM, Hoyer JD, Bowen DA, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Kay NE, Slager SL. Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. Leuk Lymphoma 2009; 50(8):1261-8.
    View PubMed
17. Zent CS, Secreto CR, LaPlant BR, Bone ND, Call TG, Shanafelt TD, Jelinek DF, Tschumper RC, Kay NE. Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab. Leuk Res 2008 Dec; 32(12):1849-56. Epub 2008 Jun 27.
    View PubMed
18. Shanafelt TD, Kay NE, Jenkins G, Call TG, Zent CS, Jelinek DF, Morice WG, Boysen J, Zakko L, Schwager S, Slager SL, Hanson CA. B-cell count and survival: Differentiating chronic lymphocytic leukemia (CLL) from monoclonal B-cell lymphocytosis (MBL) based on clinical outcome. Blood 2008 Nov 17. [Epub ahead of print]
    View PubMed
19. Zent CS, Call TG, Shanafelt TD, Tschumper RC, Jelinek DF, Bowen DA, Secreto CR, Laplant BR, Kabat BF, Kay NE. Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. Cancer 2008 Oct 15; 113(8):2110-8.
    View PubMed
20. Shanafelt TD, Kay NE, Call TG, Zent CS, Jelinek DF, LaPlant B, Morice WG, Hanson CA. MBL or CLL: which classification best categorizes the clinical course of patients with an absolute lymphocyte count >or= 5 x 10(9) L(-1) but a B-cell lymphocyte count <5 x 10(9) L(-1)? Leuk Res 2008 Sep; 32(9):1458-61. Epub 2008 Jan 07.
    View PubMed
21. Palmer S, Hanson CA, Zent CS, Porrata LF, Laplant B, Geyer SM, Markovic SN, Call TG, Bowen DA, Jelinek DF, Kay NE, Shanafelt TD. Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemia. Br J Haematol 2008 May; 141(5):607-14. Epub 2008 Apr 01.
    View PubMed
22. Zent CS, Ding W, Schwager SM, Reinalda MS, Hoyer JD, Jelinek DF, Tschumper RC, Bowen DA, Call TG, Shanafelt TD, Kay NE, Slager SL. The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. Br J Haematol 2008 May; 141(5):615-21. Epub 2008 Mar 27.
    View PubMed
23. Shanafelt TD, Geyer SM, Bone ND, Tschumper RC, Witzig TE, Nowakowski GS, Zent CS, Call TG, Laplant B, Dewald GW, Jelinek DF, Kay NE. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008 Mar; 140(5):537-46.
    View PubMed
24. Tschumper RC, Geyer SM, Campbell ME, Kay NE, Shanafelt TD, Zent CS, Nowakowski GS, Call TG, Dewald GW, Jelinek DF. Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clin Invest 2008 Jan; 118(1):306-15.
    View PubMed
25. Thurmes P, Call T, Slager S, Zent C, Jenkins G, Schwager S, Bowen D, Kay N, Shanafelt T. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk Lymphoma 2008 Jan; 49(1):49-56.
    View PubMed
26. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007 Dec; 48(12):2412-7.
    View PubMed
27. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res 2007 Dec; 31(12):1737-40. Epub 2007 Jul 19.
    View PubMed
28. Bowen DA, Call TG, Jenkins GD, Zent CS, Schwager SM, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma 2007 Dec; 48(12):2412-7.
    View PubMed
29. Clive S Zent, Timothy G Call, Tait D Shanafelt, Diane F Jelinek, Renee C Tschumper, Charla R Secreto, Deborah A Bowen, Susan M Geyer, Brian F Kabat, Betsy R LaPlant, Wenting Wu, Neil E Kay. Alemtuzumab and rituximab for initial treatment of high risk, early stage chronic lymphocytic leukemia (CLL). Blood 2007 Nov 16; 118(part 1, issue 11):611a.
    View PubMed
30. Maddocks-Christianson K, Slager SL, Zent CS, Reinalda M, Call TG, Habermann TM, Bowen DA, Hoyer JD, Schwager S, Jelinek DF, Kay NE, Shanafelt TD. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. Br J Haematol 2007 Nov; 139(3):398-404.
    View PubMed
31. Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Sloan JA, Call TG. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. Br J Haematol 2007 Oct; 139(2):255-64.
    View PubMed
32. Zent CS, Kay NE. Chronic lymphocytic leukemia: biology and current treatment. Current Oncology Reports 2007 Sep; 9(5):345-52.
    View PubMed
33. Zent CS, Kay NE. Chronic lymphocytic leukemia: biology and current treatment. Curr Oncol Rep 2007 Sep; 9(5):345-52.
    View PubMed
34. HM Lacy, CS Zent, NE Kay, TG Call, TD Shanafelt, SA Schichman. FcRH1, FcRH2, and FcRH5 are consistently expressed on the surface of chronic lymphocytic leukemia cells. Leukemia & Lymphoma 2007 Sep; 48(Suppl 1):S127.
    View PubMed
35. Browning RL, Geyer SM, Johnson AJ, Jelinek DF, Tschumper RC, Call TG, Shanafelt TD, Zent CS, Bone ND, Dewald GW, Lin TS, Heerema NA, Grever MR, Kay NE, Byrd JC, Lucas DM. Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. Leuk Res. 2007 Jul 18.
    View PubMed
36. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007 Jun 1; 109(11):2291-8.
    View PubMed
37. Ding W, Zent CS. Diagnosis and management of autoimmune complications of chronic lymphocytic leukemia/ small lymphocytic lymphoma. Clin Adv Hematol Oncol 2007 Apr; 5(4):257-61.
    View PubMed
38. Nowakowski GS, Hoyer JD, Shanafelt TD, Geyer SM, LaPlant BR, Call TG, Jelinek DF, Zent CS, Kay NE. Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. Mayo Clin Proc 2007 Apr; 82(4):449-53.
    View PubMed
39. Rockacy J, Viozzi CF, Zent CS. Mantle cell lymphoma presenting as a slowly enlarging lesion of the floor of mouth in a healthy 72-year-old female: Report of a case. J Oral Maxillofac Surg 2007 Feb; 65(2):333-7.
    View PubMed
40. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF, Tschumper R, Bone ND, Dewald GW, Lin TS, Heerema NA, Smith L, Grever MR, Byrd JC. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007 Jan 15; 109(2):405-11. Epub 2006 Sep 28.
    View PubMed
41. Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, Dewald GW. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006 Oct 1; 24(28):4634-41.
    View PubMed
42. Shanafelt TD, Byrd JC, Call TG, Zent CS, Kay NE. Narrative review: initial management of newly diagnosed, early-stage chronic lymphocytic leukemia. Ann Intern Med 2006 Sep 19; 145(6):435-47.
    View PubMed
43. Lee HB, Pulido JS, Buettner H, Salomao D, Zent CS, Link TP. Intravascular B-cell lymphoma (angiotropic lymphoma) with choroidal involvement. Arch Ophthalmol 2006 Sep; 124(9):1357-9.
    View PubMed
44. Zent CS, Call TG, Hogan WJ, Shanafelt TD, Kay NE. Update on risk-stratified management for chronic lymphocytic leukemia. Leuk Lymphoma 2006 Sep; 47(9):1738-46.
    View PubMed
45. Nora EH, Hamacher KL, Zent CS, Ghosh AK. Indolent systemic mastocytosis as the cause of a long history of unexplained hypotensive episodes. South Med J 2006 Aug; 99(8):876-9.
    View PubMed
46. Osborn NK, Ustundag Y, Zent CS, Wiesner RH, Rosen CB, Narayanan Menon KV. Factor XII deficiency acquired by orthotopic liver transplantation: case report and review of the literature. Am J Transplant 2006 Jul; 6(7):1743-5.
    View PubMed
47. Osborn NK, Ustundag Y, Zent CS, Wiesner RH, Rosen CB, Menon KVN. Factor XII deficiency acquired by orthotopic liver transplantation: Case report and review of the literature. Am J Transplant 2006 Jul; 6(7):1743-5.
    View PubMed
48. Fink SR, Smoley SA, Stockero KJ, Paternoster SF, Thorland EC, Van Dyke DL, Shanafelt TD, Zent CS, Call TG, Kay NE, Dewald GW. Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006 Jun; 167(2):177-81.
    View PubMed
49. Shanafelt TD, Lee YK, Call TG, Nowakowski GS, Dingli D, Zent CS, Kay NE. Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leuk Res 2006 Jun; 30(6):707-12. Epub 2005 Dec 01.
    View PubMed
50. Stockero KJ, Fink SR, Smoley SA, Paternoster SF, Shanafelt TD, Call TG, Zent CS, Van Dyke DL, Kay NE, Dewald GW. Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006 Apr 15; 166(2):152-6.
    View PubMed
51. Nowakowski GS, Dewald GW, Hoyer JD, Paternoster SF, Stockero KJ, Fink SR, Smoley SA, Remstein ED, Phyliky RL, Call TG, Shanafelt TD, Kay NE, Zent CS. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol 2005 Jul; 130(1):36-42.
    View PubMed
52. Nowakowski GS, Call TG, Morice WG, Kurtin PJ, Cook RJ, Zent CS. Clinical significance of monoclonal B cells in cerebrospinal fluid. Cytometry Part B, Clinical Cytometry 2005 Jan; 63B(1):23-7.
    View PubMed
53. Nowakowski GS, Call TG, Morice WG, Kurtin PJ, Cook RJ, Zent CS. Clinical significance of monoclonal B cells in cerebrospinal fluid. Cytometry B Clin Cytom 2005 Jan; 63(1):23-7.
    View PubMed
54. Zent CS, Kay NE. Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. Curr Oncol Rep 2004 Sep; 6(5):348-54.
    View PubMed
55. Zent CS, Chen JB, Kurten RC, Kaushal GP, Lacy HM, Schichman SA. Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium. Leuk Res 2004 May; 28(5):495-507.
    View PubMed
56. Kyasa MJ, Hazlett L, Parrish RS, Schichman SA, Zent CS. Veterans with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death. Leuk Lymphoma 2004 Mar; 45(3):507-13.
    View PubMed
57. Kohli M, Zent C, Hutchins LF, Safar M, Dotson, P, Mehta P. The academic hematology-oncology firm: a model for postgraduate cancer education. J Cancer Educ 2004 Spr; 19(1):45-9.
    View PubMed
58. Zent CS, Kay NE. Update on monoclonal antibody therapy in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2004 Feb; 2(2):107-13.
    View PubMed
59. Zent CS, Kay NE. Update on monoclonal therapy in chronic lymphocytic leukemia. Clinical Advances in Hematology and Oncology 2004; 2:107-113.
    View PubMed
60. Kyasa MJ, Parrish RS, Schichman SA, Zent CS. Autoimmune cytopenia does not predict poor prognosis in chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2003 Sep; 74(1):1-8.
    View PubMed
61. Zent CS, Zhan FG, Schichman SA, Bumm KHW, Lin P, Chen JB, Shaughnessy JD. The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res 2003 Sep; 27(9):765-74.
    View PubMed
62. Monson T, Schichman SA, Zent CS. Linezolid-induced pure red blood cell aplasia. Clin Infect Dis 2002 Aug 1; 35(3):E29-31.
    View PubMed
63. Kohli M, Fink LM, Spencer HJ, Zent CS. Advanced prostate cancer activates coagulation: a controlled study of activation markers of coagulation in ambulatory patients with localized and advanced prostate cancer. Blood Coagul Fibrinolysis 2002 Jan; 13(1):1-5.
    View PubMed
64. Joseph L, Scott MA, Schichman SA, Zent CS. Localized herpes simplex lymphadenitis mimicking large-cell (Richter's) transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Hematol 2001 Dec; 68(4):287-91.
    View PubMed
65. Zent CS, Kyasa MJ, Evans R, Schichman SA. Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry data. Cancer 2001 Sep 1; 92(5):1325-30.
    View PubMed
66. Zent C. Anemia and chronic disease. US Medicine 2001; 37(5 Suppl):5-8.
67. Kohli M, Schichman SA, Fink L, Zent CS. Use of HFE mutation analysis for hereditary hemochromatosis: the need for physician education in the translation of basic science to clinical practice. South Med J 2000 May; 93(5):469-71.
    View PubMed
68. Zent CS, Ratajczak J, Ratajczak MZ, Anastasi J, Hoffman PC, Gewirtz AM. Relationship between megakaryocyte mass and serum thrombopoietin levels as revealed by a case of cyclic amegakaryocytic thrombocytopenic purpura. Br J Haematol 1999 May; 105(2):452-8.
    View PubMed
69. Zent CS, Wilson CS, Tricot G, Jagannath S, Siegel D, Desikan KR, Munshi N, Bracy D, Barlogie B, Butch AW. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood 1998 May 1; 91(9):3518-23.
    View PubMed
70. Zent C, Rowley JD, Nucifora G. Rearrangements of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: in vitro and in vivo studies. Leukemia 1997 Apr; 11 Suppl 3:273-8.
    View PubMed
71. Zent CS, Mathieu C, Claxton DF, Zhang DE, Tenen DG, Rowley JD, Nucifora G. The chimeric genes AML1/MDS1 and AML1/EAP inhibit AML1B activation at the CSF1R promoter, but only AML1/MDS1 has tumor-promoter properties. Proc Natl Acad Sci U S A 1996 Feb 6; 93(3):1044-8.
    View PubMed
72. Zent C, Kim N, Hiebert S, Zhang DE, Tenen DG, Rowley JD, Nucifora G. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties. Current Topics in Microbiology & Immunology 1996; 211:243-52.
    View PubMed
73. Zent C, Smith P. Study of the effect of concomitant food on the bioavailability of rifampicin, isoniazid and pyrazinamide. Tubercle & Lung Disease 1995 Apr; 76(2):109-13.
    View PubMed
74. Zent C. Drug allergy. S Afr Med J 1994 May; 84(5):281-6.
75. Zent CS. Toxicity of anti-tuberculous medication. The Southern African Journal of Epidemiology and Infection 1994; 9(1):5-9.
76. Zent CS, Allin R, Folb PI. Prediction of amikacin dose requirements in neutropenic patients with haematological disease. S Afr Med J 1993 Nov; 83(11):853-4.